Background: Perioperative strategies can significantly influence long-term cancer outcomes. Dexmedetomidine, an a 2 -
(e.g. natural-killer cytotoxicity), 9, 10 and, 2) facilitate metastatic progression through the direct effects of prostaglandins and catecholamines on a residual malignant disease or its microenvironment. 8, 11 Despite being relatively short, the perioperative period involves numerous risk factors, but also presents unexploited opportunities to improve the overall patient survival. 12 A prominent aspect of surgery that can be manipulated so that cancer outcomes can be potentially improved is the choice of anaesthetic/analgesic approaches, which have been suggested to impact various endocrinological, immunological, and cancer-related outcomes in animal and human studies. 6,13e18 Dexmedetomidine is an a 2 -adrenoreceptor agonist that is used as a sedative and an adjuvant to anaesthetic strategies in the perioperative context. Increasingly used in the USA and recently entering the European market, 19 it is unique in exerting sedative, anxiolytic, analgesic, and sympatholytic effects, and exhibiting opioid-and anaesthetic-sparing effects. 20e22 Considering these effects of dexmedetomidine, specifically its sympatholytic effects, one can presume beneficial actions in the perioperative care of cancer patients. However, in vitro studies have shown increased cell survival and cell proliferation by dexmedetomidine, 23, 24 and in vivo studies have reported both potentiation 25, 26 and lack of effect of dexmedetomidine on tumour progression. 27, 28 Notably, most in vivo studies employed chronic manipulations of a 2 -adrenoceptor, and assessed the growth of a primary tumour, rather than using dexmedetomidine acutely and studying the metastatic process, which are most relevant to the clinical settings in cancer patients. We studied the influences of the short-term use of clinically relevant doses of dexmedetomidine on the progression of cancer metastases in rodent models in the context of stress and surgery. To support the generalizability of the outcomes beyond the specific characteristics of a single tumour line, we employed three types of cancer and different approaches of tumour-cell inoculation in rats and mice, studying the metastatic efficacy and progression in various organs of males and females. In two tumour models, in addition to studying the actual number of metastases developed 21 days following dexmedetomidine and tumour administration, we assessed an earlier index of metastatic efficacydretention of tumour cells in different organs at 24 h following i.v. tumour inoculation. This index, whilst reflecting the numbers of viable tumour cells in an organ that can potentially form solid metastases, 29e31 also more specifically reflects the potential initial impact of dexmedetomidine administration (12e24 h) on early processes of metastasis formation (survival of tumour cells in the circulation and extravasation into an organ). 
Methods

Animals
Drugs and their administration
Dexmedetomidine, an a 2 -adrenergic agonist, and yohimbine, an a 2 -adrenergic antagonist (both Sigma, Rehovot, Israel), were administered (s.c. 0.5 ml; 21G needle), employing a slow release vehicle (see Supplementary material 1.1), which prevents initial high plasma levels and maintains prolonged exposure to the drugs. Phenoxybenzamine (Sigma, Rehovot, Israel), an irreversible a 1 -adrenoceptor antagonist, was dissolved in propylene glycol (s.c., 1 ml kg À1 ; 1.5 or 4 mg kg
À1
; see 32 for dose).
Dexmedetomidine schedule
To closely simulate the dexmedetomidine clinical kinetics and impact, the doses used in most experimentsd5 and
dwere chosen to reach an average plasma level of 0.7 and 1.5 ng ml
À1
, respectively. These doses are based upon our testing of reflex loss, which were correlated to plasma concentration in a study that systematically assessed such relations. 33 For further elaboration and results for these studies, see Supplementary material 3.1. 
General experimental procedures
Editor's key points
Recent evidence points to both positive and negative effects of perioperative management on long-term outcomes in cancer surgery. The impact of dexmedetomidine on tumour metastasis was tested in three rodent cancer models. Dexmedetomidine had dose-dependent deleterious effects on markers of tumour-cell metastasis, which require further translational and clinical validation.
shown in Fig. 1 ; changes to this procedure, if any, are detailed within specific experiments. All three tumour-cell lines were obtained from the National Institutes of Health tumour bank, tested for Mycoplasma, and maintained frozen in liquid nitrogen until use. MADB 106 is a mammary adenocarcinoma syngeneic to F344 rats, CT26 is colorectal carcinoma syngeneic to BALB/c mice, and 3LL is Lewis lung carcinoma syngeneic to C57BL/6 mice. Cells were thawed and cultured in monolayer in complete media (RPMI-1640 media supplemented with 10% heat-inactivated foetal calf serum, 50 mg mL À1 gentamicin, 2 mM L-glutamine, 0.1 mM non-essential amino acids, and 1 mM of sodium pyruvate (Biological Industries, Kibbutz Beit Haemek, Israel) in 100% humidity, 5% CO 2 in air at 37 C.
DNA radiolabelling for the assessment of organ tumour retention was accomplished by adding 0.5 mCi ml For tumour-cell injection, rats or mice were lightly anaesthetised with isoflurane, and 4 Â 10 5 tumour cells kg
À1
in PBS (0.5 ml for rats or 100 ml for mice) containing 0.1% bovine serum albumin were injected into the tail vein or external carotid artery (ECA). For the assessment of organ tumour-cell retention, animals were sacrificed with 100% inhaled CO 2 21 h after the inoculation with 125 IDUR-labelled tumour cells, and specific organs were removed and placed in a g-counter to assess the percent radioactivity retained in the organ. Tumour retention was calculated using the following formula:
(radioactivity count of organ À background radioactivity) Â 100/(radioactivity count of the total injected cell suspension À background radioactivity)
Induction and counting of MADB 106 and CT26 experimental metastases
Rats or mice were anaesthetised with isoflurane, and unlabelled MADB 106 or CT26 tumour cells, respectively, were injected into the tail vein (rats) or spleen (mice, through a 0.5 cm abdominal incision, followed by splenectomy). Three weeks later, the animals were sacrificed, and their lungs (rats) or livers (mice) were removed, and visible surface metastases were counted by a blinded researcher. For details of the injection procedures and metastases counting, see Supplementary material 1.2 and 1.3.
External carotid artery injection procedure
This procedure enables a controlled administration of tumour cells directly to the brain without disturbing brain blood flow 34 (see Supplementary material 1.4). This approach and the administration of CT26 cells through the spleen involve surgical procedures of~15 min.
Stress procedures
Experimental laparotomy
Briefly, rats were anaesthetised with 2.5% isoflurane, and a 4 cm midline abdominal incision was performed, opened for 20 min, and sutured with 3-0 nylon thread (see Supplementary material 1.5).
Restraint stress
Rats were placed in a perforated clear Plexiglas tube (7 cm diameter, 40 cm length) for 180 min; at 90 min, they were removed temporarily for tumour injection.
Wet-cage stress
Rats were placed for 90 min in standard transparent Plexiglas cages containing 2 cm water at room temperature (ad libitum food and water). The animals were returned to their home cages 15 min before the tumour-cell injection.
Measuring body temperature and maintaining normothermia
To prevent potential hypothermia induced by dexmedetomidine, heating pads (heating cage bedding to 39e40 C; inactive pads in controls) were activated for 8 h (duration of dexmedetomidine hypothermic effects) starting 30 min after dexmedetomidine injections. The degree of hypothermia induced by dexmedetomidine and the ability of the heating pad to induce normothermia were verified a priori (see Supplementary material 3.2).
Statistical and power analyses
One-/two-/three-way ANOVA were used in all studies. When significant group differences were found, Fisher's protected least significant difference (PLSD) post hoc tests were used to test specific pairwise differences. For all analyses, P<0.05 was considered significant. Power analyses were conducted separately for the different outcomes, given their different variances. For the index of lung tumour retention (LTR) in MADB 106 and 3LL tumours, provided a 1.5 effect size or greater, and based on the known variance in these indices in our laboratory, a power of 80% is achieved with 7.2 animals. For the index of metastasis number in MADB 106 and CT26 tumour models, and given variance estimations from our previous studies employing these indices, 12 animals per group are needed to achieve a power of 80% provided a 2.1 effect size.
Results
MADB 106 lung tumour retention in naïve rats
Dexmedetomidine significantly [F (4, 91) ¼34.82, P<0.0001] increased MADB 106 lung tumour retention (LTR) dose dependently in both sexes, starting at a sub-hypnotic dose of Fig. 2A) . These deleterious effects occurred when dexmedetomidine was injected simultaneously with MADB 106 cells, as well as when injected 2, 6, or 12 h before (PLSD's P<0.0001) (Fig. 2B) . When dexmedetomidine was given with yohimbine, a selective a 2 -adrenorecptor antagonist, its effects on MADB 106
LTR were prevented, but were not significantly affected when given with phenoxybenzamine, an a 1 -adreneceptor agonist (Fig. 3A) . Hypothermia induced by dexmedetomidine did not mediate the effects of these drugs, as maintaining normothermia did not reduce their impact [F (2, 40) ¼18.193, P<0.0001; Fig. 3B ].
Impact of dexmedetomidine on MADB 106 lung tumour retention under stress and surgery conditions (Fig. 4AeC) . As expected, dexmedetomidine had deleterious effects in non-stressed and non-operated animals starting from 5 mg kg À1 h À1 (Fig. 4AeC) . In animals subjected to wet-cage stress, dexmedetomidine exerted similar deleterious effects as in non-stressed animals, further increasing LTR beyond the effects of stress [F (2, 143) ¼14.826, P<0.0001] (Fig. 4A) . Interestingly, under restraint stress, dexmedetomidine interacted with the effects of stress, not exhibiting deleterious effect beyond the effects of stress, and in one low dose (2.5 mg kg À1 h À1 ), dexmedetomidine significantly reduced them (PLSD P¼0.0077) (Fig. 4B) . In animals undergoing laparotomy, dexmedetomidine did not exert deleterious effects above the effects of surgery, indicating it had no interaction with the effects of surgery. At a higher dose (20 mg kg À1 h À1 ), however, dexmedetomidine had deleterious effects in the operated animals (PLSD P<0.05) (Fig. 4C) . We repeated this experiment in animals subjected to laparotomy four times, employing different doses of dexmedetomidine (2.5e20 mg kg 
Tumour retention in other organs
The administration of tumour cells through the external carotid artery (ECA) induced markedly greater brain tumour retention (Fig. 5A ) compared to the administration through the tail vein (Fig. 5B ) in rats. Importantly, dexmedetomidine increased tumour retention in rats and mice in both administration routes and in all organs tested, including brain, lung, liver, kidney, and muscle, and excluding brain in rats inoculated via the tail vein {ECA in rats (Fig. 5A) (Fig. 5AeC) . 
Liver metastases of CT26 colorectal cancer cells in BALB/C mice, and lung metastases of MADB 106 in F344 rats
Dexmedetomidine administered once before tumour cells caused a significant dose-dependent increase in the number of metastases counted 3 weeks later in both modelsdin rats only employing the higher hypnotic dose (20 mg kg À1 h À1 ) (F 93,2 ¼5.002, P¼0.0086) (Fig. 6A) , and in mice in both the low sub-hypnotic dose and the higher hypnotic dose (3 or 12.5 mg kg À1 h À1 , respectively) (F 2,36 ¼4.252, P¼0.022) (Fig. 6B) .
Discussion
Relation between the experimental model and the clinical setting
The drug schedules of dexmedetomidine employed were chosen to simulate clinical plasma levels, and behavioural and physiological effects. In the clinical setting, cancer patients are exposed to dexmedetomidine during surgery for removal of the primary tumour, and/or for up to a day following it. Thus, the potential effects of dexmedetomidine on long-term cancer outcomes would most likely be mediated through its direct and indirect effects on a residual disease, especially on preexisting micro-metastases and scattered single tumour cells in the circulation and lymphatic systems. We employed tumour models that simulate metastatic processes related to a residual disease, rather than studying the potential effects of dexmedetomidine on the development of a primary tumour. Additionally, as dexmedetomidine has known effects on stress responses and is known to reduce catecholamine release, 20 we also tested its effects in two stress paradigms.
Deleterious outcomes of dexmedetomidine and their biological significance
Dexmedetomidine exerted dose-dependent deleterious effects in non-stressed animals at doses of 5 mg kg À1 h À1 and higher. Under stress conditions, the effects of dexmedetomidine on metastasis development depended on the stress/surgery paradigm and the dose of dexmedetomidine used, as can be expected given the complexity of stress and inflammatory responses. Whilst dexmedetomidine did not elevate metastatic propensity in the restraint-stress paradigm, in the wet-cage paradigm, dexmedetomidine worsened the effects of stress at all doses tested. When employing dexmedetomidine in the surgical setting, no beneficial effects were noted. In some doses and tumour models, only mild deleterious effects of dexmedetomidine were noted, whilst in other conditions, dexmedetomidine caused a consistent deleterious effect beyond the effects of surgery. Taken together, it is likely that, when combined with stress or surgery in our studies, dexmedetomidine reduced the upsurge of catecholamines, alleviated nociception and pain, and reduced inflammation, all of which are expected to reduce metastatic progression. 12 Simultaneously, however, dexmedetomidine also exerted deleterious effects through different mechanisms, and thus, the net effects at the lower to moderate doses (2.5, 5, and 10 mg kg À1 h
À1
, respectively) were mixed, depending on the stress paradigm and tumour model. On the other hand, at moderate and higher hypnotic doses (10e20 mg kg À1 h À1 ), still common in the clinical setting, the deleterious effects of dexmedetomidine dominated in all three tumour models studied, which also involved surgical procedures.
To test whether the short-term effects of dexmedetomidine on organ tumour retention translate to long-term effects, we applied two models quantifying actual metastases 3 weeks following tumour-cell administration (CT26 liver metastases in mice and MADB 106 lung metastases in rats). Dexmedetomidine increased the metastasis number in both models, ), one-way ANOVA indicated significant group differences (F 7,28 ¼8.718, p<0.0001). B) Dexmededetomidine similarly increased tumour retention in male rats (n¼43) both under normothermia or hypothermia conditions. One-way ANOVA indicated significant group differences (F 2,40 ¼18.193, p<0.0001),
: indicates a significant increase relative to the control vehicle group (PLSD, p < 0.05) C indicates a significant increase from vehicle group (PLSD, p < 0.05). Data presented as mean (SEM).
indicating the biological significance of a single exposure to dexmedetomidine in the context of circulating cancer cells, and supporting the hypothesis that the effects of a relatively short perioperative exposure to dexmedetomidine could have detrimental effects on long-term clinical cancer outcomes.
To further test the generalizability of the findings, we used an additional syngeneic tumour line (3LL, Lewis lung carcinoma) and employed a different administration approach that is unique in targeting the brain, whilst also studying other organs for tumour retention. This procedure also involves surgical manipulations to expose the ECA for tumour inoculation. Dexmedetomidine had deleterious effects in all organs tested in this model, and the same outcomes were noted when F344 rats were subjected to MADB 106 ECA tumour inoculation. Natural killer (NK) cells play a role in restricting lung metastases in both models, but have no impact on brain tumour retention and brain metastases. 34, 35 Thus, given the similar deleterious effects
of dexmedetomidine in all organs tested, the impact of dexmedetomidine seems to be mediated, at least partly, by an organ-independent mechanism, as further discussed below. We retrospectively analysed data from 1404 operated patients with non-small cell lung cancer (NSCLC), of which 241 were treated with dexmedetomidine perioperatively. 36 The use of dexmedetomidine was associated with statistically and clinically significant lower survival rates at 5 yr post-surgery, an effect evident only in patients receiving above-median doses of dexmedetomidine (>100 mg per patient). These associative findings correspond well with the causative experimental outcomes presented here.
Potential mechanisms
Given that, in non-stressed animals, dexmedetomidine had reliable deleterious effects at mild doses and higher in all tumour models, organs, and conditions tested, we hypothesise that these effects are mediated through multiple mechanisms, including non-tumour-specific mechanisms, and generic metastatic-promoting effects. Notably, the effects of dexmedetomidine were initiated shortly following its administration, and subsided along with cessation of its behavioural effects, indicating quickly inducible and reversible mechanisms. Thus, immune mechanisms might include reduced innate anti-metastatic immunity that can quickly and transiently be modulated, specifically NK cell cytotoxicity, which controls lung and liver metastases in all tumour models used, 30, 34, 35 but not brain metastasis. Non-immune mechanisms might include changes in vascular dilation and constriction, alteration in the expression of epithelial adhesion molecules, and increased capillary permeability to circulating tumour cells, all of which have been suggested to be modulated by dexmedetomidine, 37, 38 as well as to impact metastatic spread.
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Fig 4. Dexmedetomidine does not attenuate the deleterious effects of wet-cage or surgery stress on MADB106 lung tumour retention, but does so at a low dose under restrainer stress. A) Wet Cage Both female and male rats (n¼71, 84 respectively) were either subjected to wet-cage stress or maintained at their home cages (control). Three-way ANOVA indicated a significant main effect for the dose of dexmedetomidine (Dexmed) (F 2,143 ¼14.826, p<0.0001) and for stress (F 1,143 ¼22.154, p<0.0001), but no significant effect for sex and no interactions. Both wet-cage stress and Dexmed elevated tumour retention significantly. B) Restraint Male rats (n¼75) were subjected to either restraint stress or maintained at their home cages. While restraint stress elevated tumour retention levels, a low dose of Dexmed (2.5 mg$kg
) abolished this effect (PLSD p¼0.0077). Two-way ANOVA indicated a significant main effect for the dose of Dexmed (F 3,56 ¼3.887, p¼0.0136) and for stress (F 1,56 ¼12.892, p¼0.0007), with no interactions. C) Surgery Male rats (n¼65) were subjected to either surgery or maintained at their home cages. Two-way ANOVA indicated a significant main effect of Dexmed (F 3,46 ¼15.091, ) affected tumour retention. Surgery had increased LTR.: indicates a significant increase in the vehicle group caused by stress. C indicates significant pair-wise difference from the respective control (vehicle) group (PLSD, p < 0.05). Data presented as mean (SEM).
Study limitations
As for any tumour model used in translational studies, the generalizability of the findings to cancer progression in humans is uncertain. We employed several tumour models of metastasis, which are syngeneic to different rodent species and strains, and found converging evidences for the deleterious effects of dexmedetomidine. The absence of a definitive mediating mechanism for the effects of dexmedetomidine in any of the tumour models used is a drawback of the study, which is addressed in our ongoing studies, yielding multiple and complex potential mechanisms. 40 Although the behavioural effects of dexmedetomidine in mice and rats suggested similar levels of sedation and plasma concentration as in patients, other biological effects might differ between species. This study focused on the effects of dexmedetomidine on cancer metastasis in naïve animals, as well as in the context of stress and surgery, similar to the perioperative setting of dexmedetomidine use in cancer patients. At sub-hypnotic to hypnotic/sedative doses, dexmedetomidine significantly increased the tumour-cell retention and the actual number and growth of metastases in well-controlled experimental conditions, and in almost all of the models implemented. This suggests the generalizability of such effects of dexmedetomidine. In the context of stress or surgery, no consistent effects of dexmedetomidine were evident at low sub-hypnotic doses; however, moderate and high doses of dexmedetomidine increased metastases in all models. These findings, and the correspondence between our animal and human outcomes, 36 warrant further clinical studies for different cancer types and other a 2 -adrenergic agonists used clinically (e.g. clonidine), and for more elaborated mechanistic research in animal models and in human cancer lines. Dexmedetomidine elevated the number of metastases counted three weeks following tumour inoculation in two animal models. A) Male (n¼45) and female F344 rats (n¼53) lungs were counted for experimental metastasis retention. Two-way ANOVA indicated a significant main effect for dexmedetomidine (Dexmed) dose (F 93,2 ¼5.002, p¼0.0086), and no effects for sex nor an interaction. B) Female mice (n¼39) livers were counted for experimental metastasis retention. One-way ANOVA indicated a significant effect for Dexmed (F 2,36 ¼4.252, p¼0.022). Dexmed elevated the number of liver metastasis significantly in both doses. C indicates significant pair-wise difference from the vehicle control group (PLSD, p < 0.05). Data presented as mean (SEM).
